Biogen Details $5.6B Apellis Deal, Sees Mid-to-High-Teens Growth and EPS Accretion by 2027

3 days ago 3

MarketBeat

Tue, March 31, 2026 astatine 9:10 AM CDT 7 min read

Biogen logo

Biogen volition get Apellis for $41 per share (about $5.6 billion upfront) positive contingent worth rights, with the woody expected to adjacent successful Q2 2026 and financed via cash, revolver borrowings and a slope word indebtedness (transaction borrowings targeted to beryllium repaid by extremity of 2027).
The woody adds 2 commercialized products—Syfovre (the archetypal FDA‑approved therapy for geographic atrophy successful an underpenetrated ~1.5M diagnosed U.S. diligent population) and Empaveli (approved successful PNH and successful uncommon kidney diseases C3G and IC‑MPGN, including pediatric indications)—plus Apellis’ ~350‑person commercialized team.
Biogen expects combined gross from Syfovre and Empaveli to turn successful the mid‑ to high‑teens for astatine slightest 2 years, with the transaction becoming progressively accretive starting successful 2027 and accelerating Biogen’s nephrology build‑out and imaginable motorboat synergy for its ain program, felzartamab.
Interested successful Biogen Inc.? Here are 5 stocks we similar better.

3 Biotech Stocks That Look Like “Sure-Fire” Winners successful 2026

Biogen (NASDAQ:BIIB) executives outlined their rationale and fiscal expectations for a projected acquisition of Apellis during a concern update call, positioning the woody arsenic a mode to adhd near-term commercialized maturation portion deepening the company’s propulsion into immunology, uncommon disease, and nephrology.

President and CEO Chris Viehbacher said Biogen has been wide astir however it evaluates mergers and acquisitions, emphasizing it is not seeking to instrumentality “a batch of signifier III risk” fixed its existing late-stage pipeline. Viehbacher noted Biogen’s pipeline is viewed internally arsenic “high-conviction,” but helium expects that pipeline “doesn’t truly commencement to lend to maturation until 2028,” with launches taking clip to scope highest sales.

→ The Often-Missed Corner of Healthcare That Wall Street Is Loving

Biogen Stock Is Mutating Into a Value Play

Viehbacher laid retired respective criteria helium said would request to beryllium met for an acquisition, including staying aligned with Biogen’s broadened absorption beyond neuroscience into “neurology, immunology, and uncommon diseases,” avoiding excessive equilibrium expanse stretch, keeping the woody size astir “$5 billion-$6 billion,” and acquiring assets astatine a terms that “still creates worth for Biogen shareholders.” He said Biogen believes Apellis fits those criteria.

Adam Keeney, Head of Corporate Development, said the acquisition would adhd “two best-in-class products” to Biogen’s maturation portfolio: Syfovre successful geographic atrophy (GA) and Empaveli crossed uncommon hematology and kidney diseases.

Read Entire Article